A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression

Journal of Clinical Psychiatry

Volumn 59, Issue 12, 1998, Pages 664-668

  Landén, Mikael ^a,c   Björling, Göran ^b   Ågren, Hans ^a   Fahlén, Tom ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Nona Älvsborgs Lan Hospital   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; PAROXETINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SEROTONIN UPTAKE; TREATMENT OUTCOME;

EID: 0032425587     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v59n1204     Document Type: Article

References (23)

1. Roose SP, Glassman AH, Walsh BT, et al. Tricyclic nonresponders: phenomenology and treatment. Am J Psychiatry 1986;143:345-348
2. Katona CL, Abou Saleh MT, Harrison DA, et al. Placebocontrolled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995;166:80-86. Correction 1995;166:544
3. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994;151:1372-1374
4. Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-393
5. Aronson R, Offman HJ, Joffe RT, et al. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 1996;53:842-848
6. Young SN. Use of tryptophan in combination with other antidepressant treatments: a review. J Psychiatry Neurosci 1991;16:241-246
7. Rickels K. Buspirone in clinical practice. J Clin Psychiatry 1990;51(9, suppl):51-54
8. Rickels K, Amsterdam JD, Clary C, et al. Buspirone in major depression: a controlled study. J Clin Psychiatry 1991;52:34-38
9. 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990;10(3, suppl): 67S-76S
10. Fahre LF. Buspirone in the management of major depression: a placebocontrolled comparison. J Clin Psychiatry 1990;51(9, suppl):55-61
11. Rickels K, Amsterdam J, Clary C, et al. Buspirone in depressed outpatients: a controlled study. Psychopharmacol Bull 1990;26:163-167
12. Harvey KV, Balon R. Augmentation with buspirone: a review. Ann Clin Psychiatry 1995;7:143-147
13. Bakish D. Fluoxetine potentiation by buspirone: three case histories. Can J Psychiatry 1991;36:749-750
14. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;52:217-220
15. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993;54:269-271
16. Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression. S Afr Med J 1997;87:534-537,540
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
18. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
19. Montgomery SA, Asberg M. A new depression rating scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
20. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale. Acta Psychiatr Scand 1987;76(suppl 334):1-100
21. Niklson IA, Reimitz PE, Sennef C. Factors that influence the outcome of placebo-controlled antidepressant clinical trials. Psychopharmacol Bull 1997;33:41-51
22. Brown WA. Placebo as a treatment for depression. Neuropsychopharmacology 1994;10:265-269
23. Frank E. Placebo as treatment for depression [commentary]. Neuropsychopharmacology 1994;10:275-277